Neoplasm Incidence in Simultaneous Pancreas and Kidney Transplantation: A Single-Center Analysis

• Published in: Transplantation proceedings Vol. 43; no. 9; pp. 3288 - 3291
• Main Authors: Girman, P., Lipar, K., Kocik, M., Kriz, J., Marada, T., Saudek, F.
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Amsterdam Elsevier Inc 01.11.2011; Elsevier
• Subjects: Adult; Biological and medical sciences; Body Mass Index; Epidemiology; Female; Follow-Up Studies; Fundamental and applied biological sciences. Psychology; Fundamental immunology; General aspects; Humans; Immunosuppressive Agents - adverse effects; Kidney Transplantation - adverse effects; Lymphoproliferative Disorders - etiology; Male; Medical sciences; Middle Aged; Neoplasms - complications; Neoplasms - etiology; Pancreas Transplantation - adverse effects; Pancreatic Diseases - complications; Postoperative Complications; Public health. Hygiene; Public health. Hygiene-occupational medicine; Renal Insufficiency - complications; Retrospective Studies; Surgery; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Tissue, organ and graft immunology; Treatment Outcome; Center; Concurrent; Transplantation; Homotransplantation; Epidemiology; Kidney; Incidence; Medicine; Treatment; Urinary system; Combined surgery; Analysis; Graft; Tumor; Pancreas
• ISSN: 0041-1345; 1873-2623; 1873-2623
• DOI: 10.1016/j.transproceed.2011.09.011

Long-term immunosuppression is associated with an increased rate of cancer. The aim of this study was to analyze the incidence of newly diagnosed tumors in simultaneous kidney and pancreas transplantation (SPKT). We retrospectively analyzed the incidence of a neoplasm among 360 diabetic subjects who consecutively underwent SPKT from 1985 to August 2010 in a single institution. Data were retrieved from the institutional registry. We evaluated the nature of all newly diagnosed malignant tumors, including posttransplantation lymphoproliferative disease (PTLD), to compare Kaplan-Meier survival rates with those of patients free of a neoplasm. The median follow-up was 8 years; the overall 5-year patient survival was 84%. In 25 patients the tumors were malignant. Almost one-fourth of the cancers represented skin tumors (3 squamous cell and 4 basal cell carcinomas). PTLD was diagnosed in 5 recipients. The cumulative survival of patients with malignancies was significantly lower than that in recipients without cancer (8-year survival by 38% vs 70%; P < .001). The mean (±SD) time to diagnosis was 6 ± 3 years. Since 2004, the 12 recipients with malignancy who were switched to sirolimus at the time of diagnosis showed survivals that were not apparently better than those who remained on the established immunosuppression (46% vs 55%; P = .71). The risk of neoplasm development was similar to that reported by other centers. Recipients of SPKT show higher incidence of cancer, though their overall survival is still significantly better than in those usually remaining on dialysis.